Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms Navigant
- Sponsors Bayer
- 12 Jul 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 15 May 2017 Planned End Date changed from 30 Jun 2017 to 31 Aug 2017.